lncRNAs function as context-dependent modulators of MTX PK/PD processes rather than primary drug targets. Current evidence is heterogeneous, future studies integrating functional genomics, PK measurements, and prospective clinical validation are required to establish lncRNAs as predictive biomarkers or therapeutic targets in MTX precision pharmacology.
Guzmán-Martín et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: